A Phase 1 interventional study of TAK-954 in Hepatic Impairment and Healthy Volunteers, sponsored by Takeda. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effect of varying degrees of hepatic function on the single dose PK of IV TAK-954.
The drug being tested in this study is called TAK-954. This study will evaluate the safety and tolerability of single intravenous doses of TAK-954 in participants with varying degrees of hepatic function.
The study will enroll approximately up to 32 participants. Participants will be enrolled in one of the 4 treatment groups based on their degree of hepatic impairment which will be determined based on Child-Pugh Score as follow:
The Child-Pugh classification will assess the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, prothrombin time, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
All participants will receive a single dose of TAK-954 0.2 mg on Day 1.
This study may have a full study design, where Group 1 to Group 4 will enroll approximately 8 participants in each group or a reduced study design, where no participants will be enrolled in Group 1 and approximately 8 participants will be enrolled in Group 2 to Group 4.
This multi-center trial will be conducted in Czech Republic and Slovakia. The overall time to participate in this study is approximately 7 weeks. Participants will remain confined to the clinic for 4 days, with 2 further out-patient visits, and will make a final visit to the clinic 10-14 days after receiving their last dose of TAK-954 for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
Drug: TAK-954
TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
Drug: TAK-954
TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
Drug: TAK-954
TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
Drug: TAK-954
TAK-954 intravenous infusion.
Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
Time frame: Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
AUClast: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Total and Free)
Time frame: Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for TAK-954 (Total and Free)
Time frame: Day 1 pre-infusion and at multiple time points (up to 96 hours) post-infusion
Number of Participants With Clinically Significant Physical Examination Findings
Time frame: Up to 14 days after the last dose of study drug (Day 15)
Number of Participants With Markedly Abnormal Electrocardiograms (ECGs)
Time frame: Up to 14 days after the last dose of study drug (Day 15)
Number of Participants With Markedly Abnormal Values of Vital Signs
Time frame: Up to 14 days after the last dose of study drug (Day 15)
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values
Time frame: Up to 14 days after the last dose of study drug (Day 15)
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline up to 30 days after last dose of study drug (Day 31)
Participants took part in the study at 2 investigative sites in Czech Republic and Slovakia from 09 November 2017 to 10 September 2018.
| Milestone | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| Started | 8 | 10 | 7 |
| Completed | 8 | 10 | 7 |
| Not completed | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| TAK-954 (Total) | 2.629 ± 19.1 | 2.440 ± 25.3 | 1.893 ± 35.4 |
| TAK-954 (Free) | 0.1381 ± 15.6 | 0.1799 ± 24.4 | 0.1778 ± 23.1 |
| hour*nanogram per milliliter (h*ng/mL) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| TAK-954 (Total) | 28.57 ± 19.2 | 23.57 ± 26.2 | 20.19 ± 32.7 |
| TAK-954 (Free) | 1.501 ± 12.0 | 1.737 ± 23.0 | 1.898 ± 19.3 |
| h*ng/mL | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| TAK-954 (Total) | 31.30 ± 20.1 | 25.44 ± 27.1 | 22.60 ± 34.3 |
| TAK-954 (Free) | 1.643 ± 13.8 | 1.875 ± 24.0 | 2.122 ± 21.8 |
| Participants | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Physical Examination Findings | 0 | 0 | 0 |
| Participants | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| Number of Participants With Markedly Abnormal Electrocardiograms (ECGs) | 0 | 0 | 2 |
| Participants | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| Number of Participants With Markedly Abnormal Values of Vital Signs | 0 | 1 | 1 |
| Participants | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values | 0 | 0 | 0 |
| Participants | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) | 2 | 3 | 1 |
Collected over TEAEs are adverse events that started after the first dose of study drug and no more than 30 days (Day 31) after the last dose of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Participants: TAK-954 0.2 mg | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Event | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/8 | 2/10 | 1/7 |
| HeadacheNervous system disorders | 1/8 | 0/10 | 0/7 |
| FlatulenceGastrointestinal disorders | 0/8 | 1/10 | 0/7 |
The safety set consisted of all participants who were enrolled and received the study drug.
| Age, Continuous(years) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| Mean | 58.5 ± 9.46 | 55.6 ± 12.25 | 57.9 ± 12.88 | 57.2 ± 11.21 |
| Sex: Female, Male(Participants) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| Female | 3 | 4 | 1 | 8 |
| Male | 5 | 6 | 6 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 10 | 7 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 8 | 10 | 7 | 25 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| Czech Republic | 3 | 3 | 2 | 8 |
| Slovakia | 5 | 7 | 5 | 17 |
| Weight(kilogram (kg)) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| Mean | 89.95 ± 17.098 | 86.77 ± 19.823 | 87.19 ± 21.331 | 87.90 ± 18.667 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| Mean | 31.1 ± 3.18 | 30.4 ± 5.02 | 27.9 ± 6.18 | 29.9 ± 4.87 |
| Height(centimeter (cm)) | Healthy Participants: TAK-954 0.2 mg | Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg | Group C, Severe Hepatic Impairment: TAK-954 0.2 mg | Total |
|---|---|---|---|---|
| Mean | 169.8 ± 11.30 | 168.0 ± 10.47 | 176.1 ± 6.28 | 170.8 ± 10.01 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Nov 2017 to primary completion in Sep 2018, 9 months.
Results were first posted in Sep 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Td-8954